HXBM (Helix Biomedix) OCF Margin %: -109.17% (As of Sep. 2012)


What is Helix Biomedix OCF Margin %?

Helix Biomedix HXBM OCF Margin % is -109.17% as of Sep. 2012.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Helix Biomedix's Cash Flow from Operations for the three months ended in Sep. 2012 was $-0.51 Mil. Helix Biomedix's Revenue for the three months ended in Sep. 2012 was $0.47 Mil. Therefore, Helix Biomedix's OCF Margin % for the quarter that ended in Sep. 2012 was -109.17%.

As of today, Helix Biomedix's current OCF Yield % is -452.24%.

The historical rank and industry rank for Helix Biomedix's OCF Margin % or its related term are showing as below:

HXBM' s OCF Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: -88

HXBM's OCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -66.52 vs HXBM: -88.00

Helix Biomedix OCF Margin % Related Terms

Helix Biomedix OCF Margin % Historical Data

* Premium members only.

The historical data trend for Helix Biomedix's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix Biomedix OCF Margin % Chart

Helix Biomedix Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -692.24 -558.08 -785.68 -328.29 -121.42

Helix Biomedix Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -139.49 -86.10 -77.21 -84.29 -109.17

HXBM vs XBIO, CBLI, ADYX: OCF Margin % Comparison

For the Biotechnology subindustry, Helix Biomedix's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helix Biomedix OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix Biomedix's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Helix Biomedix's OCF Margin % falls into.


Helix Biomedix OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Helix Biomedix's OCF Margin for the fiscal year that ended in Dec. 2011 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2011 )/Revenue (A: Dec. 2011 )
=-2.296/1.891
=-121.42 %

Helix Biomedix's OCF Margin for the quarter that ended in Sep. 2012 is calculated as

OCF Margin=Cash Flow from Operations (Q: Sep. 2012 )/Revenue (Q: Sep. 2012 )
=-0.512/0.469
=-109.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -109.17% mean?
Helix Biomedix (HXBM) has a OCF Margin % of -109.17% as of Sep. 2012. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Helix Biomedix and its competitors.
Is Helix Biomedix's OCF Margin % too high?
Helix Biomedix's current OCF Margin % is -109.17%.
How does Helix Biomedix's OCF Margin % compare to XBIO and CBLI?
Helix Biomedix's OCF Margin % of -109.17% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Helix Biomedix and its competitors. Helix Biomedix's current OCF Margin % is -109.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix Biomedix stock overvalued right now?
Helix Biomedix (HXBM) has a current OCF Margin % of -109.17%. The current OCF Margin % is -109.17%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Helix Biomedix (HXBM), the current OCF Margin % is -109.17% as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix Biomedix Business Description

Address 19125 North Creek Parkway, Suite 120, Bothell, WA, USA, 98011
Helix Biomedix Inc is a Delaware-based biopharmaceutical company that focuses on the early-stage development of peptide-based therapeutics for dermatology and skin health. The Company is in the preclinical stage, advancing a rare disease drug program for xeroderma pigmentosum, and plans to seek orphan drug designation before entering clinical development. Leveraging its proprietary peptide technology, Helix BioMedix aims to address unmet needs in rare dermatological conditions and has a history of developing patented bioactive peptides for topical personal care use.